These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32761925)

  • 1. Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells.
    Naeem A; Dakshanamurthy S; Walthieu H; Parasido E; Avantaggiati M; Tricoli L; Kumar D; Lee RJ; Feldman A; Noon MS; Byers S; Rodriguez O; Albanese C
    Prostate; 2020 Oct; 80(14):1233-1243. PubMed ID: 32761925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.
    Saeed K; Rahkama V; Eldfors S; Bychkov D; Mpindi JP; Yadav B; Paavolainen L; Aittokallio T; Heckman C; Wennerberg K; Peehl DM; Horvath P; Mirtti T; Rannikko A; Kallioniemi O; Östling P; Af Hällström TM
    Eur Urol; 2017 Mar; 71(3):319-327. PubMed ID: 27160946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning.
    Turanli B; Zhang C; Kim W; Benfeitas R; Uhlen M; Arga KY; Mardinoglu A
    EBioMedicine; 2019 Apr; 42():386-396. PubMed ID: 30905848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.
    Zhao SG; Jackson WC; Kothari V; Schipper MJ; Erho N; Evans JR; Speers C; Hamstra DA; Niknafs YS; Nguyen PL; Schaeffer EM; Ross AE; Den RB; Klein EA; Jenkins RB; Davicioni E; Feng FY
    Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):229-36. PubMed ID: 25986914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing.
    Issa NT; Kruger J; Wathieu H; Raja R; Byers SW; Dakshanamurthy S
    BMC Bioinformatics; 2016 May; 17(1):202. PubMed ID: 27151405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
    Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
    Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting new indications for approved drugs using a proteochemometric method.
    Dakshanamurthy S; Issa NT; Assefnia S; Seshasayee A; Peters OJ; Madhavan S; Uren A; Brown ML; Byers SW
    J Med Chem; 2012 Aug; 55(15):6832-48. PubMed ID: 22780961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
    Fang E; Zhang X; Wang Q; Wang D
    Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.
    Longo J; Mullen PJ; Yu R; van Leeuwen JE; Masoomian M; Woon DTS; Wang Y; Chen EX; Hamilton RJ; Sweet JM; van der Kwast TH; Fleshner NE; Penn LZ
    Mol Metab; 2019 Jul; 25():119-130. PubMed ID: 31023626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway.
    Dong F; Yang P; Wang R; Sun W; Zhang Y; Wang A; Chen M; Chen L; Zhang C; Jiang M
    Prostate; 2019 Aug; 79(11):1284-1293. PubMed ID: 31212374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures.
    Mosaad E; Chambers K; Futrega K; Clements J; Doran MR
    BMC Cancer; 2018 May; 18(1):592. PubMed ID: 29793440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.
    Gravina GL; Festuccia C; Millimaggi D; Tombolini V; Dolo V; Vicentini C; Bologna M
    Urology; 2009 Aug; 74(2):452-7. PubMed ID: 19285710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug repositioning framework by incorporating functional information.
    Wu Z; Wang Y; Chen L
    IET Syst Biol; 2013 Oct; 7(5):188-94. PubMed ID: 24067419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer.
    Schnepp PM; Ahmed A; Escara-Wilke J; Dai J; Shelley G; Keller J; Mizokami A; Keller ET
    BMC Cancer; 2021 Dec; 21(1):1316. PubMed ID: 34879849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditionally reprogrammed normal and primary tumor prostate epithelial cells: a novel patient-derived cell model for studies of human prostate cancer.
    Timofeeva OA; Palechor-Ceron N; Li G; Yuan H; Krawczyk E; Zhong X; Liu G; Upadhyay G; Dakic A; Yu S; Fang S; Choudhury S; Zhang X; Ju A; Lee MS; Dan HC; Ji Y; Hou Y; Zheng YL; Albanese C; Rhim J; Schlegel R; Dritschilo A; Liu X
    Oncotarget; 2017 Apr; 8(14):22741-22758. PubMed ID: 28009986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer.
    Kryza T; Bock N; Lovell S; Rockstroh A; Lehman ML; Lesner A; Panchadsaram J; Silva LM; Srinivasan S; Snell CE; Williams ED; Fazli L; Gleave M; Batra J; Nelson C; Tate EW; Harris J; Hooper JD; Clements JA
    Mol Oncol; 2020 Jan; 14(1):105-128. PubMed ID: 31630475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Microwell-mesh: A high-throughput 3D prostate cancer spheroid and drug-testing platform.
    Mosaad EO; Chambers KF; Futrega K; Clements JA; Doran MR
    Sci Rep; 2018 Jan; 8(1):253. PubMed ID: 29321576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of comprehensive two-dimensional prostate cancer cell membrane chromatographic system and network pharmacology for characterizing membrane binding active components from Radix et Rhizoma Rhei and their targets.
    Zheng L; Chen S; Cao Y; Zhao L; Gao Y; Ding X; Wang X; Gu Y; Wang S; Zhu Z; Yuan Y; Chen X; Chai Y
    J Chromatogr A; 2018 Aug; 1564():145-154. PubMed ID: 29895409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer.
    Lovell S; Zhang L; Kryza T; Neodo A; Bock N; De Vita E; Williams ED; Engelsberger E; Xu C; Bakker AT; Maneiro M; Tanaka RJ; Bevan CL; Clements JA; Tate EW
    J Am Chem Soc; 2021 Jun; 143(23):8911-8924. PubMed ID: 34085829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.